恩度联合肝动脉化疗栓塞预防肝癌术后复发的研究

摘要

目的 探讨恩度联合肝动脉化疗栓塞(TACE)降低肝癌术后复发率,延长患者生存期的效果.方法 收集2010年1月至2013年12月70例确诊肝癌行根治性手术切除且预防性行TACE的患者资料,术后单纯行TACE治疗(45例)的设为对照组,恩度联合TACE治疗(25例)的设为观察组,统计两组术后复发率、生存率及生存时间.结果 两组患者基线资料比较差异无统计学意义(P>0.05).对照组的术后复发率为48.9%,观察组术后复发率为24.0%,差异有统计学意义(P<0.05).对照组的1、2、3年生存率分别67.8%、65.3%、64.1%,中位生存时间为29个月,观察组的1、2、3年生存率分别87.2%、76.2%、75.0%,中位生存时间为42个月.对照组和观察组的3年累积生存率差异有统计学意义(P<0.05).结论 恩度联合TACE较单纯TACE治疗预防肝癌术后复发效果好,能有效降低肝癌术后复发率,延长了患者的生存期.%Objective To evaluate the efficacy of Endostar combined with transcatheter arterial chemoembolization(TACE)to reduce the recurrence rate of hepatocellular carcinoma(HCC)and prolong the patient's survival. Methods 70 HCC patients who were admitted and treated with radical resection in our hospital were enrolled during January 2010 to December 2013. 45 patients were treated with TACE(Control group)and the other 25 patients(Experiment group)with TACE plus Endostar. The recurrence rate,survival rates and survival time were analyzed. Results No obvious difference was found in the baseline data between two groups(P>0.05). Compared with the control group,the experimental group had significantly lower recurrence rate(24.0% vs 48.9%,P<0.05),prolonged median survival time(42 months vs 29 months)and higher 3-year cumulative survival rate(P<0.05). In the control group,1-,2-,3-year survival rates were 67.8%,65.3% and 64.1%,correspondingly 87.2%, 76.2%and 75.0% in experiment group. Conclusion Compared with TACE alone,TACE plus Endostar signifi cantly decreases postoperative recurrence rate and prolongs the patient's survival,which may be a better methods in preventing postoperative recurrence of HCC.